Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | NCOA1 | Q15788 | 2/20 | 0.34 |
| ▸ | NCOA3 | Q9Y6Q9 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13841393 | 0.72 | IRAK4 (0.41) | IRAK4ALDH1A1KDM4EHTTNCOA1 | |
| SCHEMBL19160402 | 0.72 | KMT2A (0.37) | IRAK4ALDH1A1LMNAHSD17B10KDM4E | |
| SCHEMBL9202302 | 0.67 | KDR (0.38) | IRAK4ALDH1A1LMNATP53HSD17B10 | |
| SCHEMBL6833209 | 0.65 | EGFR (0.42) | ALDH1A1LMNATP53HSD17B10HTT | |
| SCHEMBL6837647 | 0.65 | EGFR (0.42) | RAB9A | |
| SCHEMBL6836416 | 0.64 | EGFR (0.46) | — | |
| SCHEMBL3528078 | 0.64 | EGFR (0.47) | LMNAHTTRAB9AKDR | |
| SCHEMBL10548235 | 0.64 | NR4A2 (0.43) | ALDH1A1LMNAKDM4EHTTHPGD | |
| SCHEMBL2395940 | 0.64 | ALDH1A1 (0.34) | ALDH1A1LMNATP53HSD17B10HTT | |
| SCHEMBL6837677 | 0.63 | ALDH1A1 (0.43) | ALDH1A1LMNATP53HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2719701-B1 | Method for the preparation of thieno[3,4-d]pyrimidin-7-yl ribosides | GILEAD SCIENCES INC (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2719701-B1 | Method for the preparation of thieno[3,4-d]pyrimidin-7-yl ribosides | GILEAD SCIENCES INC (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2719701-A1 | methods for the preparation of thieno[3,4-d]pyrimidin-7-yl ribosides | GILEAD SCIENCES, INC. (US) | 2014-04-16 | — | — | EP | disclosed |
| EP-2719701-A1 | methods for the preparation of thieno[3,4-d]pyrimidin-7-yl ribosides | GILEAD SCIENCES, INC. (US) | 2014-04-16 | — | — | EP | disclosed |
| EP-2396340-B1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES INC (US) | 2013-12-18 | — | — | EP | disclosed |
| US-8012942-B2 | Carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8012942-B2 | Carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8012942-B2 | Carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| WO-2010093608-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-08-19 | — | — | WO | disclosed |
| US-20100203015-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100203015-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100203015-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-08-12 | — | — | US | disclosed |
| EP-1018514-B1 | NF-$g(k)B INHIBITORS CONTAINING INDAN DERIVATIVES AS THE ACTIVE INGREDIENT | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2004-05-12 | — | — | EP | disclosed |
| US-6734180-B1 | NF-κB inhibitor comprising an indan derivative as an active ingredient | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2004-05-11 | — | — | US | disclosed |
| US-6703421-B1 | ADMINISTERING NF-KAPPA B INHIBITOR | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2004-03-09 | — | — | US | disclosed |
| EP-1132093-A1 | PREVENTIVES OR REMEDIES FOR MYOCARDITIS, DILATED CARDIOMYOPATHY AND CARDIAC INSUFFICIENCY CONTAINING NF-KAPPA B INHIBITORS AS THE ACTIVE INGREDIENT | SUNTORY LIMITED (JP) | 2001-09-12 | — | — | EP | disclosed |
| EP-1018514-A1 | NF-$g(k)B INHIBITORS CONTAINING INDAN DERIVATIVES AS THE ACTIVE INGREDIENT | SUNTORY LIMITED (JP) | 2000-07-12 | — | — | EP | disclosed |
| EP-0225182-B1 | CEPHALOSPORIN COMPOUNDS | ICI PHARMA (FR) | 1993-02-10 | — | — | EP | disclosed |
| US-5013731-A | Bactericides | ICI PHARMA (FR) | 1991-05-07 | — | — | US | disclosed |
| EP-0225182-A2 | Cephalosporin compounds | ICI PHARMA (FR) | 1987-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100203015-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, TYMP, MTAP | IRAK4 1108/4885ALDH1A1 3094/4885LMNA 1447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.